Cinitapride monotartrate
Based on 1 Customer Validation
Cinitapride monotartrate is a 5-HT1A and 5-HT4 agonist. Cinitapride monotartrate is also a 5-HT2A and D2 antagonist. Cinitapride monotartrate can be used for the research of functional dyspepsia.
For research use only. We do not sell to patients.
- Purity : 99.78%
- CAS No.: 1207859-16-2
- Formula: C25H36N4O10
- Molecular Weight:552.57
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[1]|
5-HT1A Receptor |
5-HT2A Receptor |
5-HT2 Receptor |
5-HT4 Receptor |
D2 Receptor |
5-HT1 Receptor |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Wistar rats with gastric ulceration[2]
-
Dosage:0.25-1 mg/kg
-
Administration:Intraperitoneal injection; 0.25-1 mg/kg; once
-
Result:Reduced haemorrhagic lesions compared with the ulcerated control group.
Decreased the percentage of ulceration to 28.76% at the highest dose (1 mg/kg).
Attenuated the increase myeloperoxidase activity (p<0.05, p<0.01).
Increased GSH-px activity in the gastric mucosa.
Chemical Information
-
CAS No. 1207859-16-2
-
Appearance Solid
-
Molecular Weight 552.57
-
Formula C25H36N4O10
-
SMILES
O=C(NC1CCN(CC2CC=CCC2)CC1)C3=CC([N+]([O-])=O)=C(N)C=C3OCC.O=C(O)[C@H](O)[C@@H](O)C(O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 4.17 mg/mL (7.55 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Purity & Documentation
References
[1]. Du Y, et al. Efficacy and safety of cinitapride in the treatment of mild to moderate postprandial distress syndrome-predominant functional dyspepsia. J Clin Gastroenterol. 2014 Apr;48(4):328-35. [Content Brief]
[2]. Alarcón de la Lastra C, et al. Effects of cinitapride on gastric ulceration and secretion in rats. Inflamm Res. 1998 Mar;47(3):131-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8097 mL | 9.0486 mL | 18.0973 mL | 45.2431 mL |
| 5 mM | 0.3619 mL | 1.8097 mL | 3.6195 mL | 9.0486 mL |